Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla Sells 155,333 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla sold 155,333 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total transaction of $121,159.74. Following the transaction, the chief executive officer now owns 1,736,883 shares in the company, valued at $1,354,768.74. The trade was a 8.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Spero Therapeutics Stock Performance

Shares of NASDAQ SPRO opened at $0.88 on Thursday. Spero Therapeutics, Inc. has a 1 year low of $0.74 and a 1 year high of $1.89. The firm’s 50 day moving average price is $0.99 and its 200 day moving average price is $1.19. The firm has a market cap of $47.81 million, a P/E ratio of 12.53 and a beta of 0.61.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Evercore ISI lowered shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a research report on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a research report on Thursday, January 30th. Finally, TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.